Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
DarioHealth ( (DRIO) ) has issued an update.
On July 23, 2025, DarioHealth Corp. held its 2025 Annual Meeting of Stockholders, where several key proposals were voted on. Stockholders elected directors to serve until the next annual meeting, ratified the appointment of Kesselman & Kesselman as auditors, and approved amendments to the 2020 Equity Compensation Plan. Additionally, they authorized a reverse stock split and an increase in authorized shares, which could impact the company’s capital structure and market positioning.
The most recent analyst rating on (DRIO) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on DarioHealth stock, see the DRIO Stock Forecast page.
Spark’s Take on DRIO Stock
According to Spark, TipRanks’ AI Analyst, DRIO is a Neutral.
The overall score reflects significant financial challenges with high leverage and negative profitability. However, positive earnings guidance and strategic corporate events, such as leadership enhancements and financial agreements, offer potential for future improvement.
To see Spark’s full report on DRIO stock, click here.
More about DarioHealth
DarioHealth Corp. operates in the digital health industry, focusing on providing digital therapeutics solutions. The company offers products and services aimed at managing chronic conditions such as diabetes, hypertension, and behavioral health, leveraging technology to improve patient outcomes.
Average Trading Volume: 155,068
Technical Sentiment Signal: Sell
Current Market Cap: $31.14M
Learn more about DRIO stock on TipRanks’ Stock Analysis page.